B. Braun supplies healthcare markets worldwide and is employing approx. 40,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.
B. Braun OEM Division System-built Solutions.
Expertise in contract manufacturing and infusion therapy products
B. Braun supplies healthcare markets worldwide and is employing approx. 40,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.
At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.
Furthermore, we provide a wide range of infusion therapy products. We supply all that is needed to admixture and infuse or inject a drug. You can order standard products or a customized version.
Project Management
Connecting Competences. Realizing Ideas.
Partnering with us provides you with complete outsourcing knowledge. Our project management teams are the experts for individual customer ideas.
We can handle manufacturing projects and will customize a product or set according to your detailed specifications.
Our project management services include:
Products
Pharmaceutical Solutions
Medical devices
Disinfection and Hygiene
Products for
B. Braun Melsungen AG
OEM Division Europe
Carl-Braun-Strasse 1
34212 Melsungen
Germany
Phone: +49 5661 71-2826
Fax: +49 5661 71-3562
service_oem@bbraun.com
www.bbraunoem.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.